|Ms. Susan B. Washer||Pres, CEO & Director||788.55k||N/A||1961|
|Mr. Stephen W. Potter||VP & Chief Bus. Officer||492.17k||N/A||1956|
|Dr. Nicholas Muzyczka||Co-Founder||N/A||N/A||N/A|
|Dr. Barry J. Byrne M.D., Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. William W. Hauswirth||Co-Founder & Member of Ophthalmology Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Richard Jude Samulski Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Terence R. Flotte M.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Jonathan I. Lieber M.B.A.||Chief Financial Officer||N/A||N/A||1970|
|Mr. Gerald Anthony Reynolds||Chief Accounting Officer, Principal Accounting Officer & Treasurer||N/A||N/A||N/A|
|Dr. Abraham Scaria Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.
Applied Genetic Technologies Corporation’s ISS Governance QualityScore as of July 1, 2022 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 7; Compensation: 9.